文献速递白血病

负载WT1和PRAME RNA的树突状细胞疫苗作为新诊断急性髓系白血病强化诱导化疗后的维持治疗

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
PubMed 文献 · Leukemia · 2023-07-28

20例不适合异基因造血干细胞移植的初诊急性髓系白血病首次完全缓解患者,接受负载两种白血病相关抗原的自体RNA树突状细胞疫苗FDC101维持治疗,每剂每个抗原2.5-5×10^6个成熟树突状细胞,每周给药至第4周、第6周、之后每月,研究期2年。治疗耐受良好,仅轻度短暂注射部位反应;20例中11例(55%)维持完全缓解,6例复发者中4例经挽救治疗后达第二次完全缓解并接受异基因移植;5年总生存率75%(95%CI:50-89),≥60岁患者中70%为长期生存者。

要点

  • 该树突状细胞疫苗维持治疗在首次完全缓解且不适合移植的急性髓系白血病患者中耐受良好。
  • 20例中11例(55%)维持完全缓解,6例复发者中4例经挽救治疗达第二次完全缓解后接受移植。
  • 5年总生存率75%(95%CI:50-89),≥60岁患者中70%为长期生存者。

核心结论

  • 该树突状细胞疫苗维持治疗在首次完全缓解的急性髓系白血病患者中耐受良好,并伴随令人鼓舞的5年长期生存。

研究设计与样本

  • 20例首次完全缓解且不适合异基因造血干细胞移植的急性髓系白血病患者接受自体RNA负载成熟树突状细胞疫苗FDC101治疗,随访安全性和长期生存。
  • 每剂每个抗原含2.5-5×10^6个成熟树突状细胞,每周给药至第4周、第6周、之后每月,研究期2年。

主要发现

  • 治疗耐受良好,仅出现轻度短暂注射部位反应。
  • 20例中11例(55%)维持完全缓解。
  • 6例复发患者中4例经挽救治疗后达第二次完全缓解并接受异基因造血干细胞移植。
  • 5年总生存率为75%(95%CI:50-89)。
  • ≥60岁患者中70%为长期生存者。

临床怎么用

  • 作者认为,对于首次完全缓解且不适合异基因造血干细胞移植的急性髓系白血病患者,该树突状细胞疫苗维持治疗耐受良好并伴随令人鼓舞的5年长期生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intensive induction chemotherapy achieves complete remissions (CR) in >60% of patients with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral azacytidine may be used as maintenance treatment in AML in first remission, but can be associated with substantial side effects, and less toxic strategies should be explored. Twenty AML patients in first CR (CR1) ineligible for allo-HSCT were treated with FDC101, an autologous RNA-loaded mature dendritic cell (mDC) vaccine expressing two leukemia-associated antigens (LAAs). Each dose consisted of 2.5-5 × 106 mDCs per antigen, given weekly until week 4, at week 6, and then monthly, during the 2-year study period. Patients were followed for safety and long-term survival. Treatment was well tolerated, with mild and transient injection site reactions. Eleven of 20 patients (55%) remained in CR, while 4 of 6 relapsing patients achieved CR2 after salvage therapy and underwent allo-HSCT. OS at five years was 75% (95% CI: 50-89), with 70% of patients ≥60 years of age being long-term survivors. Maintenance therapy with this DC vaccine was well tolerated in AML patients in CR1 and was accompanied by encouraging 5-year long-term survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fløisand Y, Remberger M, Bigalke I, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023. PMID: 37507426. doi:10.1038/s41375-023-01980-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。